Buprenorphine prior authorization review. The department shall review its prior authorization policy on buprenorphine-containing products provided to Medical Assistance program recipients. On the first day of the 7th month beginning after the effective date of this subsection .... [LRB inserts date], and every 6 months thereafter, the department shall submit to the standing committees of the legislature with jurisdiction over health under s. 13.172 (3) a report describing the department's findings on the prior authorization policy on buprenorphine-containing products and its progress on eliminating prior authorization requirements for buprenorphine-containing products in populations where removal of prior authorization is appropriate.
Assigned Number |
Title![]() |
Version Date | Publication Type | Other Location | Language |
---|---|---|---|---|---|
P-02294 | Medicaid Prior Authorization Policy for Buprenorphine-Containing Products for Medication-Assisted Treatment | December 13, 2018 |
PDF
|
None | English |
P-02294 | Medicaid Prior Authorization Policy for Buprenorphine-Containing Products for Medication-Assisted Treatment, June 2019 | July 10, 2019 |
PDF
|
None | English |
P-02294 | Medicaid Prior Authorization Policy for Buprenorphine-Containing Products for Medication-Assisted Treatment, May 2020 | May 22, 2020 |
PDF
|
None | English |